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ABSTRACT
Schlafen 11 (SLFN11) is a member a family of proteins that can be found in mammals. Members
of this family are involved in important functions. SLFN11 in particular has been identified as a
restriction factor for several evolutionarily disparate viruses such as HIV-1 and Flaviviruses and
to play an important role in DNA repair, sensitizing cells to chemotherapy. Despite its relevance
SLFN11 remains largely uncharacterized. The aim of this research was to achieve a more
comprehensive understanding the regulation mechanism of SLFN 11 expression. Before our
research, it was only known that type I interferon (IFN) regulates SLFN11 levels. However, we
have demonstrated that SLFN11 expression is controlled by type I interferon-dependent and independent mechanisms. Among the latter protein kinase C- and calcium-regulated-signaling
pathways are of relevance. More important, we have also established that during viral infectioninduced SLFN11 upregulation the relevance of these mechanisms vary depending on the ability of
the virus to block the type I IFN system. Therefore, our findings have revealed the complexity of
the regulation of the expression of this innate immune protein and evidenced important gaps in our
knowledge.
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INTRODUCTION
The Schlafen family
Schlafen (SLFN) is a family of proteins that can be found in mammals, these genes have
been specially conserved in mice and humans1,2, in mice these genes are confined to the
chromosome 11 and in humans they are in the chromosome 17. SLFN proteins can be divided in
three groups depending on their molecular weight, Group I goes from 37 to 42 kDa, Group II from
58 to 58 kDa and the last Group III from 100 to 104 kDa1–3 (Fig. 1). Group I and II of SLFN family
can be found in the cytoplasm and group III is nuclear4. A unique domain can be found in all of
the SLFN proteins called Slfn box which function is not known3,4, there is another component of
SLFN protein the poly AAA motif that help for GTP and ATP binding5 also intervenes in protein
degradation6, more over there is an SWDAL domain composed by the sequence Ser-Trp-Ala-AspLeu2. When all motif work together they can lead to RNA remodeling and can metabolize RNA2,3.
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In mice 10 different SLFNs have been identified (SLFN1, SLFN1L, SLFN2, SLFN3,
SLFN4, SLFN5, SLFN8, SLFN9, SLFN10, and SLFN14), and five in human (SLFN5, SLFN11,
SLFN12, SLFN13, SLFN14)1,2,7,8.
Mouse SLFNs
Several functions of the SLFN proteins have described in mouse models and some of them
have been studied in detail5,9–12, SLFN2 has a role in innate immunity against viral and bacterial
infections13, and is also implicated in osteoclastogenesis. The latter case seems to be by the
activation of osteoclast precursors via RAC110. In addition mouse SLFN2 participates in
suppression of cyclin D1 and inhibition of malignant cell growth14. SLFN1 has a similar activity
on the suppression of cyclin D1 controlling cell proliferation5. Potentially through this mechanism
SLFN1 also reduces the endothelial progenitor cell growth15. Moreover SLFN3 is downregulated
upon activation of CD4+T cells 16, suggesting a regulatory role of this protein in maintenance of
quiescence. Additionally SLFN3 has an important role in intestinal mucosa aging. The expression
of this protein can be from 8 to 10 times lower in aged colon mucosa12,17. Importantly,
overexpression of SLFN3 into colon cancer cells increases levels of cell differentiation, reduces
the tumor sphere, and increases the effectiveness of chemotherapy by increasing the intracellular
drug transport6. Similar to SLFN3, mouse SLFN4 mRNA is downregulated after macrophage
activation and high levels of this protein are associated to reduce the myelopoiesis 8. Therefore,
group I and II mouse SLFNs seem to negatively regulate cell proliferation. In contrast, group III
SLFNs are associated with control of immune responses and viral replication. For example,
increased levels of SLFN8 are found in autoimmune encephalomyelitis18 and SLFN14 impairs
influenza virus and varicella zoster virus infections19 .
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Human SLFNs
Humans SLFNs belong to groups II (SLFN12 and 12L) and III (SLFN 5, 11, 13, 14) 2. As
the mouse counterparts, human SLFN12 is implicated in regulation of cellular processes linked to
cell differentiation and apoptosis. For example this protein plays an important part during placenta
development by impairing translation of specific ER proteins, leading to cellular apoptosis.
Apoptosis is crucial for placenta implantation and growth2021. In addition SLFN12 influences
enterocytic differentiation in intestinal cells2223 and high levels of expression of SLFN12 in
prostate cancer is associated to a less aggressive phenotype24.
Group III human SLFNs are implicated in control of viral replication. In particular SLFN11 and
13 has been demonstrated to restrict infection by HIV-1 and flaviviruses. Central in the anti-HIV1 activity these proteins degrades tRNAs25,26. Interestingly, SLFN5 that lacks this activity is not
active against HIV-1 and instead seems to have a role in negatively controlling cancer cells 14,27,28.
SLFN14 seems to have a role in platelet generation since mutations in this protein are clinically
associated to low count of platelets and their function29,30.
Role of SLFN11 in human diseases
The most well characterized protein in the SLFN family is SLFN1131,32. This protein has
been demonstrated to act as a viral restriction factor against evolutionarily divergent viruses such
as HIV-1 and flaviviruses and to impair DNA damage repair in cancer cells. The role of SLFN11
in both diseases depend on the ability of this protein to prevent changes in the tRNA repertoire. In
the case of HIV-1 and DNA damage repair SLFN11-induced tRNA degradation prevents
translation of viral or host DNA damage repair proteins that are encoded in codon biased
messengers32–34. In the case of flavivirus infection SLFN11 opposes to viral-induced tRNA
downregulation, although the mechanism is unknown35. The ability of SLFN11 to negative
3

regulate the levels of ataxia-telangiectasia-mutated and Rad3-related, proteins required for DNA
damage repair, determine that this protein is a main predictor (biomarker) of cancer response to
chemotherapy agents36–42.
Regulation of expression of SLFN proteins
The relevance of the SLFN proteins in controlling cell cycle, cell differentiation, apoptosis,
DNA damage repair and viral infections indicate the importance of understanding the mechanisms
that regulate the cellular levels of these proteins. This is the main goal of my research. When I
started this work, the only mechanism described to regulate SLFN protein levels was the type I
interferon (IFN) system2. This group of interferons is composed by IFN-α, IFN-β, IFN-ε, IFN-κ,
and IFN-ω, and all of them are encoded in the chromosome 9 in humans43. Almost all nucleated
human cells can produce IFN-α and IFN-β43. Upon binding to a common receptor, type I IFNs
activate three of the Janous kinases (JAKs): JAK1,JAK2 and tryrosin kinase 2 (TYK2), that in turn
activate signal transducers and activators of transcription (STATs) 1 and 2. Phosphorylated STAT1
and STAT2 binds to interferon regulatory factor 9 (IRF9) forming a complex that bind to promoter
of a group of genes called interferon-stimulated genes (ISG) (Fig. 2). SLFN proteins are part of
the ISG 43. Furthermore, MAPK signaling has been implicated in the type I IFN signaling pathway
that regulates expression of some of the SLFN proteins2,14
Significance.
SLFN11 is a type I interferon (IFN)-induced protein that has anti-viral activity against
phylogenetically distant viruses such as HIV-142 and flaviviruses35. Additionally new studies have
extensibility showed that SLFN11 have an important role during cancer chemioresistance
development in response to treatment.

4

Therefore, SLFN11 is a biomarker or predictor for relevant diseases. Understanding the
molecular mechanism that regulates SLFN11 expression will allow us to modulate the levels of
this protein affecting these diseases. However, the mechanisms that regulate SLFN11 expression
are ill-defined, and the goal of this research was to understand better these mechanisms at the
molecular level. In order to fulfill this goal I completed the following aims:
Specific Aim 1: To determine mechanisms of regulation of SLFN11 expression during viral
infection
We focused on three phylogenetically distant viruses that are differentially affected by
SLFN11. West Nile Virus (WNV) is a positive-sense single-stranded virus of the flaviviridae
5

family, vesicular stomatitis virus (VSV) is a negative-sense single-stranded virus of the
rhabdoviridae family, and human immunodeficiency virus-1 (HIV-1) a retrovirus. In contrast to
VSV, which escapes SLFN11 restriction, the other two viruses are impaired by this host protein.
Furthermore, infection by VSV and WNV, but not by HIV-1 robustly triggers type I IFN signaling,
a major regulator of the expression of SLFN11.
Specific Aim 2: To establish the effect of type I IFN-dependent and -independent stimuli on
the activity of the SLFN11 promoter.
A 1.3 kb SLFN11 promoter (chr17 33,700,532 - 33,700,847) was reported. This DNA
region was cloned upstream eGFP to generate a simple reporter system that allows us study
promoter regulation by Fluorescence-activated cell sorting (FACS) analysis. Different stimuli
discovered in aim 1 to regulate SLFN11 protein levels in cells will be evaluated in this system.
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MATERIALS AND METHODS
Cell culture.
HEK293, SupT1, and A172 cells were obtained from the American Type Culture Collection
(Manassas, VA). Human peripheral blood mononuclear cells (PBMCs) where obtained from two
donors using peripherical blood samples and purified using Ficoll Paque™. HEK293 and A172
cells were maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM); PBMCs and SupT1 cells
were maintained in RPMI 1640. These culture media were supplemented with 10% fetal bovine
serum (FBS), 1% penicillin and streptomycin, 1% nonessential amino acids (NEAA), and 1%
sodium pyruvate. VSV engineered to express eGFP. A replication-defective HIV-1 reporter virus
(Hluc) was used, which expresses long terminal repeat (LTR)-driven luciferase from the negative
factor (NEF) slot and contains a large deletion in envelope (ENV)44. Hluc was generated by
calcium phosphate transfection of the corresponding HIV-1 expression plasmid (pHluc; 15μg) and
the VSV glycoprotein G (VSV-G)-encoding plasmid pMD.G (5μg) into HEK293T cells, as
described previously44. All work involving VSV and HIV-1, was performed in a BSL-2 laboratory
in accordance with biosafety practices described in The University of Texas at El Paso Biological
Safety Manual.
Immunoblotting.
Full procedures for protein detection by immunoblotting have been described previously45.
Brieﬂy, cellular lysates were obtained by lysing cells with 2X Laemmli buffer( prepared with : 4%
SDS, 20% Glycerol, 0.004% bromophenol blue 1.25M Tris-Cl, pH6.8 and 10% 2mercaptoethanol) and boiling for 10 min. Cell lysates were resolved by SDS-PAGE for 2:30 hrs.
at 100 volts using 1x running buffer (10 x running buffer was prepared with: 30.0 g of Tris base,
144.0 g of glycine, and 10.0 g of SDS in 1000 ml of H2O adjust pH to 8.3 and transferred using 1x

7

transfer buffer (10x transfer buffer was prepared with: Tris 15.2g Glycine 72.1g SDS 5.0g and
500ml H2O) overnight(18 hrs) onto polyvinylidene diﬂuoride (PVDF) membranes(bought from
Biorad) at 100 mA at 4°C. Membranes were blocked in Tris-buffered saline (TBS) containing 10%
milk for 1 h and then incubated with the corresponding primary antibody diluted in TBS–5% milk–
0.05% Tween 20 (antibody dilution buffer). Full-length SLFN11 was detected with anti-Slfn11
antibody E-4 (Santa Cruz Biotechnology) (1/500). The Slfn11 was detected with anti-Slfn11
antibody D-2 (Santa Cruz Biotechnology) (1/500). Tetherin (BST-2) was detected with anti-BST2 antibody (Santa Cruz Biotechnology) (1/500). α -Tubulin was detected as a loading control with
antibody from clone B-5-1-2 (Sigma) (1/4,000). Membranes were incubated overnight at 4°C with
primary antibodies, whereas anti α -tubulin monoclonal antibody (MAb) was incubated for 30min
at 25°C. Primary antibody-bound membranes were washed in TBS–0.1% Tween 20, and bound
antibodies were detected with goat anti-mouse IgG-horseradish peroxidase (HRP) (Sigma)
(1/2,000), followed by chemiluminescence detection. Densitometry of selected bands was
quantiﬁed based on their relative intensities using Image Studio software (Li-Cor, Lincoln, NE).
IFN-α ELISA.
IFN- α levels were quantiﬁed in the cell supernatants of infected cells by an ELISA (catalog
numbers 41115-1 for IFN-α; PBL Assay Science). ELISAs were performed according to the
manufacturer’s instructions, 1:7- point standard curve where prepared in a sample matrix, sample
buffer, standard and samples where added into the well and the incubation were performed at room
temperature shaking at 550 rpm 30 sec then incubated at 4°C for 18hrs, samples were washed one
time, antibody was added and incubated at room temperature for 1hr then washed 3 times, HRP
was added and incubated 1hr at room temperature, TMB substrate is added for 30min and
incubated in the dark at room temp, stop solution is added and samples were read using 450nm.
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Transient Transfection
Transient transfection where performed seeding HEK293 cells at 3x106 cells in a T75, 24hrs
after seeding were calcium-phosphate transfected with the corresponding transfer plasmid derived
from pEZX-LvPFO2 (slfn11 promoter) using 12μg, and incubated at 37°C for 48hrs, culture media
must be replaced with fresh media 24hrs after transfection.
Cell treatments
HEK293 transient transfected with pEZX-LvPFO2 plasmid where seeded in a 24 well plate
at 1x10^5 cell per well in a total volume of 400μl, cell where incubated for 24hrs at 37°C, 50μl of
media was removed for each treatment used, treatment where prepared in a total volume of 50μl
and then added into the well, treatments where used at this concentrations: PMA at 100μM using
8μl, Ionomycin 1/2000 dilution using 4μl, IFN-α at 5,000 units, IFN-β at 5,000 units, N-Fat at
1.187mM using 33.9μl, SR302 at 100μM using 4ul, CSA at 1/1000 using 4.8μl and Jak at 250μM
using 1.6μl, after treatment cells where incubated for 24hrs and 48hrs.
FACS assay.
HEK293 cells were seeded onto 24-well plates (1x105 cells/well) and allowed to grow
overnight. The next day, the cells were treated with different compounds and incubated at 37°C
for 24hrs and 48hrs. Cells were harvested and resuspended in a total volume of 500μl. The cells
were then analyzed by ﬂow cytometry using a Gallios ﬂow cytometer (Beckman Coulter) using
fluorescent detector channel FL1-A and a total of 10,000 cells were counted for each sample.
Virus infectivity assay.
All cell lines infected with WNV, VSV were seeded in T25 cell culture ﬂasks (2.5x10^5
cells in a 2-ml total volume) and allowed to grow overnight. The following day, the cells were
infected with the respective viruses and incubated at 37°C for 1h. Cells were subsequently washed
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three times with serum-free medium to remove input virus, replenished with maintenance medium
and incubated at 37°C, after 48hrs cell lysates were collected.
Single-round infectivity assay.
A172-derived cells were seeded onto 24-well plates (2x10^4 cells/well) and allowed to
grow overnight. The next day, cells were infected with HΔEeGFP and HΔELuc and incubated at
37°C, after 48hrs cell lysates were collected.
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RESULTS
Virus infection upregulates SLFN11 expression.
It has been reported that SLFN proteins are induced by type I-interferon (I IFN) signaling2.
Our laboratory recently discovered that West Nile virus (WNV) infection induces SLFN11 an
effect that coincide in time with a virus-induced surge of type I IFN secretion35. However, the
induction mechanism is unknown. In order to investigate the role of type I IFN in the ability of
WNV to induce SLFN11, cells were infected at a multiplicity of infection of 10 (MOI:10) in the
presence of different inhibitors including Cyclosporin A (0.1uM), ethylene glycol tetra acetic acid
(EGTA) (0.5mM), NFAT inhibitor (Cayman 13855, 100uM) and JAK (tofacitinib 100nM). Fortyeight hours later expression of SLFN11 was evaluated in these cells by immunoblotting. α-tubulin
was detected as loading control in these experiments. Cell lysates obtained from untreated cells
were serially diluted to find SLFN11 protein concentrations that were non-saturating. For example
we selected amounts of protein that give a clear signal in the X-ray films in about 5 mins of
exposure. Typically they were in the linear part of the detection system, since two-fold dilutions
of these lysate amounts correspondingly reduced the amount of SLFN11 detected by half. Using
these conditions we obtained the results in Figure 3. This experimental strategy was applied to all
the immunoblots included in this work.
Cyclosporin A and EGTA +were included in the study for their role in counteracting WNVinduce calcium-signaling and NFAT inhibitor because this is the main transcription factor
activated by calcium signaling, whereas JAK is central in the initiation of type I IFN signaling.
In correspondence with a previous report35 data in Figure 3 indicated that WNV induces SLFN11.
Importantly inhibition of JAK signaling completely abrogated this effect. Upon type I IFN receptor
binding JAK is activated initiating a signaling cascade that end in transcriptional activation of
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interferon-stimulated genes, such as SLFN11. Therefore, these results indicate that WNV induces
SLFN11 in a type I IFN-dependent manner. Interestingly, Nuclear factor of activated Tcells(NFAT) inhibitor only partially reduced WNV-induced SLFN11 upregulation, but in contrast
EGTA and Cyclosporin A(CsA) which prevent Ca-signaling required for NFAT activation, failed
to mimic the effect of NFAT inhibitor. These data suggest that NFAT could be activated in a Caindependent manner via I IFN signaling during WNV infection. In further support that JAK and
NFAT inhibition were acting via type I IFN signaling, we observed that these inhibitors favored
WNV replication 8- and 2-fold, respectively, as compared to untreated cells of cells exposed to
EGTA or CsA, at 48h post-infection (Data not shown).

To better understand the regulation of SLFN11 expression during viral infections we
determined the effect of vesicular stomatitis virus (VSV) infection and HIV-1 on the levels of this
host protein. VSV infection triggers an important type I IFN response, but HIV-1 notoriously block
type I IFN at multiple steps46.
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Furthermore, SLFN11 impairs HIV-1 but not VSV infection35. Therefore, these two model
viruses are expected to be informative about the viral regulation of SLFN11 expression. A172
cells were infected with VSV (MOI 1) or HIV-1 (MOIs 1 and 10) and 48 hrs later the levels of
SLFN11 in these cells were determined by immunoblot analysis. Data in Figure 4 indicated that
VSV infection potently upregulated SLFN11 expression.

Densitometry analysis (Fig. 5) showed a 2.6-fold increase in the α-tubulin-normalized
SLFN11 levels. Similarly two single-round infection HIV-1 also induced SLFN11 (Fig. 6) and
this effect was MOI-dependent. HΔEeGFP at MOI 10 induced 1.4 fold the expression of SLFN11
whereas at MOI 1 SLFN11 levels were not modified (Fig. 7).
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HΔELuc that was used a saturating concentration (MOI cannot be calculated for this virus)
upregulated SLFN11 around 10-fold. Therefore, these data demonstrate that viral infection induces
SLFN11 expression.
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In order to investigate the role of type I IFN in the effect of these viruses on SLFN11
expression, we measured levels of this cytokine in the cell supernatant by ELISA (Fig. 8). This
increase in SLFN11 expression correlated with a marked production of IFNα in the supernatant of
the infected cells (3,978.6 pg/ml) as measured by ELISA. In addition, VSV infection triggers
expression of tetherin, another type I IFN-stimulated gene43. However, the levels of type I IFN in
the HIV-1 infected cells were similar to those in non-infected cells (Fig 8). These results further
supported the concept that SLFN11 is induced by viral infections in type I IFN-dependent and independent manners. (All of these results were done in triplicates during the same experiment).
Type I IFN-independent mechanisms of SLFN11 upregulation.
To investigate type I IFN-independent pathways in the regulation of SLFN11 expression
primary cells were evaluated. Due to their role in HIV-1 infection in vivo we determined the effect
of several stimuli on the expression of this protein in primary CD4+ T cells isolated from two
donors. These cells were treated with Phorbol myristate acetate (PMA) (20nM), ionomycin (5nM),
Phytohemagglutinin (PHA) (5ug/ml), PMA plus ionomycin (20nM/5nM), TNFα (10ng/ml) and
IL-4 (50 ng/ml). At 48hrs post stimulation, levels of SLFN11 in these cells were determined by
immunoblot analysis using non-saturating amounts of cell lysates as described above.
In these experiments α-tubulin was detected as loading control. Data in Figure 9-10
showed that treatments with PMA, ionomycin, PHA, PMA pus ionomycin and IL4 upregulates
SLFN11 expression. In donor I, densitometry analysis indicated that PMA increased in 2-fold
SLFN11 expression compared with non-treated whereas ionomycin only activated 1.7 folds.
A synergistic effect was found between these two drugs since 2.2-fold increase were
observed with their combination. PHA also potently (2.5 fold) activated SLFN11 expression
whereas the effect of IL4 was more modest (1.5 folds). Similar results were observed in donor II.
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Although PMA or ionomycin alone failed to upregulate SLFN11 expression, their combination
activated 1.7. PHA was also potent causing a 2-fold increase but IL4 failed. Notoriously, TNFα
failed to enhance SLFN11 expression in both donors.

These results indicated that PMA in combination with ionomycin, and PHA potently
upregulate SLFN11 in two different donors. These stimuli are known to act independently of the
type I IFN signaling. PHA and ionomycin trigger Ca-dependent signaling and PMA is a protein
kinase activator.
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To determine whether type I IFN-independent of SLFN11 was relevant in different cell
types we determine the effect of these compounds in the human cell lines HEK293 (epithelial
cells) and SUPT1 (CD4+ T cells). Cells were stimulated with a panel of compounds and SLFN11
and α-tubulin were measured by immunoblotting as described above. PMA (20nM), ionomycin
(5nM) and PMA + ionomycin (20nM/5nM) stimulated SLFN11 production at both 24 and 48 hrs
post-treatment in both cell lines, although the response in HEK293 was more evident (Fig. 11).
However, TNFα (10ng/ml), IL-4 (50 ng/ml), and PHA (5ug/ml) failed to do so (data not shown).
Quantification of these immunoblots (Fig. 12) indicated that at 48 hrs HEK293 SLFN11
levels increased in 2.3 fold for PMA (2 at 24 hrs), 2 for ionomycin (1.3 at 24 hrs), and 2.2 for PMA
plus ionomycin (1.2 at 24 hrs).
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At this time point in SUPT1 cells levels increased by 2.2 folds for PMA (1.4 at 24 hrs), 4.6
folds for ionomycin (1.9 at 24 hrs), and 4 for PMA pus ionomycin (1.8 at 24 hrs). Importantly,
PMA and ionomycin upregulated SLFN11 expression in SUPT1 and HEK293 cells without
increasing Tetherin (Fig. 11), suggesting that these stimuli acted in a type I IFN-independent way.
In sum, these results indicated that PMA and ionomycin upregulate SLFN11 expression.
Signaling pathway analysis (Fig. 13) indicate that PMA/PKC could promote SLFN11
upregulation via AP-1- or Nf-Kβ-mediated transcription and inomycin via NFAT and AP-1.
However, the lack of an effect of TNFα on SLFN11 upregulation argues against an important role
for Nf-Kβ. AP-1 activation could proceed via PKC/SEK1/JNK or PKC/ERK1/2, and
Ca/Calcineurin/SEK1/JNK while NFAT is activated by Calcineurin (Fig. 13).
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This plasmid was transfected into HEK293 cells and 24 hrs later the cells were distributed
to different treatments, and 24 and 48 hrs post-stimulation eGFP mean intensity of fluorescence
(MFI), an indication of the amount of eGFP molecules in the whole culture, were calculated by
FACS. Treatments included PMA (20nM), ionomycin (5nM), PMA + ionomycin (20nM/5nM),
IFNα (5,000 U/ml) and IFNβ (5,000 U/ml).
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As MFI values in Figure 14. indicate, the SLFN11 promoter expression was stronger at 48
hrs post-stimulation although the pattern of response was similar to that of 24 hrs. Surprisingly
20

PMA was a stronger stimulus for this promoter than type IFNs. PMA augmented by 1.4 fold the
promoter activity and this effect did not increase in combination with ionomycin that alone did not
have effect on the promoter activity. In contrast, IFN β but not α stimulated the promoter activity
but in a lower magnitude (1.2 folds). At 48 hrs PMA and IFN β also increased the activity of the
promoter by 1.6 and 1.2 folds respectively (Fig. 14). These findings demonstrated that the SLFN11
promoter analyzed here responds to PMA stimulation, as the endogenous promoter, but not to
ionomycin or type I IFN indicating that important regulatory elements of the endogenous promoter
are missing in the 1.3 kbs sequence.
Next we characterized the transcription factors implicated in the PMA stimulation of this
promoter. PMA activates PKC that could promote SLFN11 upregulation via AP-1(Fig. 13) since
a role of Nf-Kβ is excluded, as discussed above.

In turn, AP-1 activation could proceed via PKC/SEK1/JNK or PKC/ERK1/2. Using
pharmacological interference, we evaluated the role of AP-1 in the ability of PMA to activate the
SLFN11 promoter in HEK293 cells. As described above, these cells were transfected with the
21

SLFN11 reporter promoter plasmid and the next day were equally distributed among different
treatments and eGFP MFI were determined 48 htrs post-stimulation. The treatments evaluated
included PMA, ionomicin, PMA plus ionomicin and IFNα and β at the same doses indicated above
alone or in combination with different inhibitors such as PMA (20nM) plus the AP-1 inhibitor
SR11302(100 μM), ionomycin (5nM) plus NFAT inhibitor (1.187mM), ionomycin plus
Cyclosporin A (.1μM), PMA (20nM) plus ionomycin (5nM) plus SR11303 (100 μM), IFNα (5,000
U/ml) plus JAK (tofacitinib 100nM), INFβ (5,000 U/ml) plus JAK (tofacitinib 100nM). Results
from this experiment corroborated our findings in Figure 15, although here IFNβ failed to activate
the promoter. Combination of ionomicin with PMA reached the same activation levels than PMA
alone as previously we found. Importantly PMA consistently enhanced the promoter activity,
increasing eGFP MFI levels by two-fold. Because in this experiment only PMA was able to
significantly activate the reporter promoter, we show in Figure 15 only the data of the PMA with
and without the AP-1 inhibitor SR11302. Data in Figure 15 indicate that PMA increased by twofold the promoter activity and that effect that was partially reduced by SR11302 by 20%,
suggesting that PMA activates the SLFN11 promoter at least partially via AP-147,48.
In further support that the studied SFN11 promoter likely respond to PMA via AP-1,
sequence scanning of the reporter promoter with the PROMO software49,50 identified one AP-1
site (CAACAGTCA). The predicted site has a dissimilarity margin of only 14.2 % with the
canonical AP-1 binding sequence (TGAGTCA).( All of these results where done in triplicate
during the experiment).
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DISCUSSION
Our results illustrate the complexity of the regulation of the expression of SLFN11. As
previously reported2 SLFN11 is regulated by type I IFN signaling in virus infected cells. However,
HIV-1 that potently blocks the interferon system51 still induces SLFN11 expression. The
mechanism employed by HIV-1 is unknown. Nevertheless, exploration of type I IFN-independent
mechanisms indicate that stimuli that activate PKC or calcium-signaling stimulate SLFN11
expression in human CD4+ T lymphocytes (primary cells) and in human cell lines of different
histological origin.
Our data also highlight that regulatory regions in the SLFN11 promoter remain
unidentified. The reported 1.3 kb promoter (chr17 33,700,532 - 33,700,847) lacks important type
I IFN-dependent and -independent regulatory regions. Yet, characterization of this promoter
indicates that the transcription factor AP-1, at least partially, regulates promoter activity in
response to PMA/PKC signaling.
It is important to identify the full-length promoter to be able to characterize in details the
regulatory elements implicated in the type I IFN-dependent and -independent mechanisms. In
collaboration with Dr. Jarrod Johnson, University of Utah, he has searched for additional SLFN11
transcriptional regulatory regions using assay for transposase-accessible chromatin (ATAC-seq)
of HIV-1 infected primary human monocyte-derived dendritic cells. In this analysis he identified
a 10.6 kb region (chr17 35,377,555 - 35,366,945) flanking the SLFN11 transcription start site that
contains four regions of HIV-1-induced open chromatin. These changes in chromatin accessibility
correspond with an innate immune response and induction of ISGs such as SLFN1146. The 10.6
kb genomic DNA is predicted to harbor binding sites of transcription factors regulated by PKC-,
Ca- and IFN-I-stimulated pathways51. Although two of these regions partially overlap with the 1.3
24

kb promoter, we hypothesize that other sites are essential for full regulatory control of SLFN11
expression in cells.
It has been reported that SLFN11 tRNase and anti-HIV-1 activity is regulated by
phosphorylation51 and SLFN11 although necessary is not sufficient for the anti-viral activity35.
Therefore, the diversity of signaling pathways that we have found in this work to regulate SLFN11
expression could impact the repertoire of post-translational modifications and SLFN11 interactors,
modulating the functions of this protein. Investigation of these aspects of SLFN11 regulation and
function deserve attention.
In summary, our data demonstrated the complexity of the SLFN11 regulation and identify
relevant gaps in our knowledge of this relevant innate immune protein.
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CONCLUSION
In sum, this research indicates that viruses can upregulate SLFN11 via type I IFNdependent and –independent mechanisms. Characterization of the later highlights the relevance of
PMA/AP-1 and calcium-driven signaling pathways in the regulation of SLFN11 expression. Our
results also revealed that the SLFN11 promoter remains partially identified since relevant type I
IFN-dependent as –independent regulatory regions are not present in the reported 1.3 kbs
promoter.
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